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Abstract. 
Management of age-related macular degeneration (AMD) is a growing public 
health challenge worldwide. At present, anti-VEGF injections offer exceptional 
visual outcomes for neovascular AMD (nvAMD) compared to prior options. 
Many new avenues of treatment are under investigation for both nvAMD and 
dry AMD, and this narrative review summarises emerging developments, in 
the process illustrating the nature of the data collected prior to interventions 
becoming available in our practices. For nvAMD, encouraging phase II trial 
results were seen with pegpleranib, an antibody against platelet derived 
growth factor, but phase III results failed to show effectiveness, and have 
been terminated. Also under investigation for nvAMD are anti-angiopoeitin 
antibodies, anti-VEGF-C and -D antibodies, “DARPins’ and even topical 
treatments. Novel means of delivering drug to the retina may also prove 
fruitful: a trial of a reservoir port is described. There is no medical treatment 
currently for atrophic AMD, but this may soon change. While visual cycle 
slowing may not have lived up to the initial hope of its usefulness, 
complement inhibition may do so, and may be particularly effective in those of 
a specific genetic subgroup. Epiretinal and other retinal implants will have a 
place for some patients. The potential for stem cell-based treatment offers 
great hope, though much work remains to be done and several trials are 
ongoing. In the next five years, a range of clinical trial results will emerge 
which may transform once again how we approach AMD, and hopefully 




The management of AMD underwent a paradigm shift with the advent of anti-
VEGFs as treatment and of OCT to monitor the condition. Presently there are 
several interesting new management options on the horizon for both 
neovascular and atrophic AMD. This narrative review summarises emerging 
interventions that may be mentioned in popular and professional press, and 
may be on our menu of treatment options to discuss with patients in the near 
future. 




When optometry and medical students are taught at university, a dramatic 
caveat should be added to much of what they learn: that it will be of no use in 
their careers to come. Knowledge is constantly replaced or updated, and 
clinical skills are at risk of being superseded by technology: for example the 
time-honoured art of direct ophthalmoscopy may be on the verge of 
redundancy (Purbrick and Chong 2015). Age-related macular degeneration 
(AMD) is the commonest cause of visual impairment in the Western world, 
and is becoming an increasing public health challenge in Asia (Velez-Montoya 
et al. 2014). The management of AMD underwent a paradigm shift in 2006 
with the advent of anti-vascular endothelial growth factor treatments (anti-
VEGFs) and optical coherence tomography (OCT).  
It should be remembered that VEGF exists for a reason: it has a physiological 
role in supporting vascular homeostasis. Animal models have compared the 
retinas of mice genetically engineered to lack soluble VEGF with the retinas of 
wild type mice with soluble VEGF (Saint-Geniez, Kurihara et al. 2009). The 
VEGF-deficient mice have shown severe disruption of choriocapillaris, retinal 
pigmented epithelial (RPE) and the neural retina. However excessive VEGF 
has been implicated in the development of macular oedema and 
neovascularization. Anti-VEGFs such as ranibizumab and aflibercept are 
licensed in the UK for management of neovascular (or ‘wet’) AMD (nvAMD), 
and for macular oedema secondary to diabetic maculopathy or retinal vein 
occlusion (Hirani S 2017). Compared to previous management options, 
replicated high quality evidence has shown them to be exceptionally effective 
in nvAMD in improving functional outcomes, like best corrected visual acuity 
(BCVA) and anatomical outcomes, like retinal thickness on OCT and leakage 
on fundus fluorescein angiography (FFA). They have improved the visual 
prospects of countless people, and have been credited with reductions in 
blindness registrations due to AMD (Borooah, Jeganathan et al. 2015). 
However in the next few years, it is hoped that new treatment options will 
emerge for both nvAMD and atrophic AMD that will give us a menu of choices 
for each of our patients. This will present interesting challenges for us in 
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assessing what treatment options are best for individual patients, and 
hopefully will lead to even better outcomes. This review summarises the data 
on emerging treatment options for AMD. It is not an exhaustive list, but aims 
to cover several specific interventions that may be mentioned in professional 
and popular press, and in the process illustrate the nature of studies that 
precede an intervention becoming available in our practices. Some relevant 
‘headline’ interim results have not yet been published in the scientific 
literature, but are available in recent corporate press releases. 
Please insert a brief paragraph describing what is meant by different phases 
of clinical studies here as it will aid the reader as they go through the rest of 
the paper 
 
Neovascular age-related macular degeneration. 
 
Anti-platelet derived growth factor agents. 
Pegpleranib (Fovista®) provides an interesting and evolving case study of the 
development of potential new treatments. It is an antibody against platelet-
derived growth factor (PDGF). Endothelial cells line blood vessels, and in the 
smallest blood vessels; capillaries and venules; endothelial cells are 
enveloped by another cell type, the pericyte. Pericytes maintain and regulate 
endothelial cells (van Dijk, Nieuweboer et al. 2015), and thereby 
microvascular health. Pegpleranib strips pericytes away, and thus was 
thought to facilitate the action of anti-VEGFs. Phase I and II studies are 
clinical trials primarily designed to investigate the safety of a drug: data on 
effectiveness from phase I/II studies are useful in planning of further trials, but 
never definitive. In a phase II study on nvAMD, participants who received 
ranibizumab and pegpleranib gained a mean of 10.6 letters after 24 weeks, 
statistically significantly better than the mean gain of 6.5 letters of those who 
received ranibizumab alone (Jaffe, Ciulla et al. 2016). With these encouraging 
results, two parallel phase 3 trials were undertaken, comparing pegpleranib 
and ranibizumab with ranibizumab alone (ClinicalTrials.gov Identifiers: 
NCT01944839 and NCT01940900). Phase III trials are designed to 
investigate safety and effectiveness, often being statistically powered to test a 
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primary outcome measured by BCVAs. In December 2016 the year one 
results were reported of the phase III trials on pegpleranib 
(https://www.novartis.com/news/media-releases/novartis-provides-update-
pegpleranib-phase-iii-clinical-trial-program-patients, accessed December 
2016). No differences in BCVA were evident between the two arms, in each 
trial, and both trials have since been terminated. Thus even with positive 
phase II trial results, the phase III trials failed to show effectiveness, and the 
future of pegpleranib as a potential ophthalmic treatment is uncertain.  
 
 
A different anti-PDGF was tested in the CAPELLA trial, an ongoing phase II 
study. Interim results were announced in a press release in September 2016 
(http://investor.regeneron.com/releasedetail.cfm?releaseid=991601, accessed 
December 2016). In CAPELLA over 500 participants were randomized to 
receive intravitreal aflibercept and rinucumab or aflibercept alone, but at 12 
weeks those receiving the combination treatment showed no benefits in terms 
of vision or anatomic outcomes. Further results are expected on the outcomes 
at week 24 and on trial completion at 52 weeks. 
 
New Subtitle ‘Tie2 Receptors’ 
Vascular endothelial cells have a receptor called Tie2, a target for two 
molecules (ligands) (Fagiani and Christofori 2013). The first ligand is 
angiopoietin 1 (ang-1), which has a physiological role mediating blood vessel 
maturation and survival. The other ligand, ang-2 contributes to angiogenesis. 
Angiogenesis is appropriate in some circumstances, such as during 
embryogenesis, tissue healing or in the menstrual cycle but clearly is 
pathological in other settings, such as in the aging macula or in a growing 
tumour. Necvasumab is a selective inhibitor of ‘ang 2’ that may have a 
therapeutic role. Necvasumab was reported as being safe when given 
intravenously for with solid tumours in 47 participants in a dose escalation 
study (Papadopoulos, Kelley et al. 2016). A trial in the US plans to recruit over 
300 patients with nvAMD in an ongoing phase II study comparing intravitreal 
aflibercept with intravitreal necvasumab (ClinicalTrials.gov Identifier: 
NCT02713204). 




New Subtitle ‘ Targeting Different Isomers’ 
 
Not all VEGF molecules are the same: in the family of VEGF molecules, many 
versions of VEGF; isoforms; exist, which differ slightly in structure and 
function (Guyot and Pages 2015). Ranibizumab inhibits all isoforms of VEGF-
A, while aflibercept inhibits multiple isoforms of VEGF-A and VEGF-B. 
However these two drugs do not inhibit other members of the VEGF family: 
VEGFs C and D. In clinical practice, cases of nvAMD are seen which respond 
neither to ranibizumab or aflibercept: is this because of the VEGF isoforms 
driving the disease in particular patients? Plasma levels of VEGF C and D 
have been found to be significantly associated with nvAMD (Teague GC 
2016). In a mouse model of choroidal neovascularization, the extent of CNVM 
activity as measured by fluorescein angiography was significantly less in mice 
given both an intravitreal inhibitor of VEGF C and D (VGX-300) and 
aflibercept compared to those treated with either agent alone (Lashkari K 
2015). In April 2016, no ‘dose-limiting toxicities’ were reported in 20 patients 
who had received up to 2.0mg of  a ‘VEGF-C/D trap therapy’ (OPT-302) 
intravitreally. Visual gains and improvements on OCT parameters occurred to 
a greater degree with OPT-302 and ranibizumab than with ranibizumab alone 
(http://www.opthea.com/pub/pdf/ASX_OPT_OPT302%20Ph%201%20Second
ary%20Endpoints_FINAL_16%2007%2026_Aust.pdf accessed Dec. 2016). 
An ongoing phase I/II trial is investigating OPT-302 for the treatment of 
nvAMD on its own compared with OPT-302 in combination with ranibizumab 
(ClinicalTrials.gov Identifier: NCT02543229). As described above however, as 
a phase I/II study the results only serve as a suggestion of potential efficacy: it 
is not guaranteed that phase III studies will confirm this. 
 
New Subtitle ‘The use of DARPins’ 
 
Designed ankyrin repeat proteins (‘DARPins’) are proteins of a type known as 
‘scaffold proteins’: they usually consist of six tightly packed repeats of 30 
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amino acids (the building blocks of all proteins). Some fixed amino acid 
positions preserve this structure, but the key is in the variable positions, which 
give DARPins a specific target. Being genetically engineered, the target of a 
DARPin can be chosen. As well as being small (and therefore in theory able 
to penetrate tissues), and specific (in theory limiting side effects), they are 
potent. A DARPin targeting VEGF-A is known as MP0112, or abicipar. In a 
phase 1 study in patients with DMO, a single intravitreal injection of 0.4mg of 
MP0112 led to half ‘maximal inhibitory’ concentrations in the aqueous after 12 
weeks, thus suggesting the clinical effects may, in theory, be long-lived 
(Campochiaro, Channa et al. 2013). A phase I/II dose-escalation study 
suggested that MP0112 was safe and perhaps effective for nvAMD (Souied, 
Devin et al. 2014). For nvAMD, the ‘REACH study’ randomized 64 patients to 
one of three intravitreal treatments: 1mg abicipar (injected at baseline, 4 and 8 
weeks), 2mg abicipar (injected at baseline, 4 and 8 weeks) or 0.5mg 
ranibizumab (injected at baseline and at 4. 8, 12 and 16 weeks), measuring 
outcomes at 20 weeks (http://www.molecularpartners.com/wp-
content/uploads/2014/10/201407_positive_phase2_for_darpin_abicipar.pdf). 
Reported interim results were that the mean BCVAs at 20 weeks showed a 
9.0 letter improvement for abicipar 2mg, 7.1 letters for abicipar 1mg and 4.7 
letters for ranibizumab. No serious adverse events were reported: 5 in total in 
the abicipar groups had an ‘ocular inflammatory adverse event’. Although not 
statistically powered for this outcome, the study confirms the merit of further 
trials. 
 
New Subtitle ‘Topical treatments’/other delivery methods 
 
Topical treatments for nvAMD are at once a counterintuitive and an extremely 
attractive option. At face value it seems unlikely that an eye drop could be an 
effective option for a macular condition. Squalamine inhibits VEGF and other 
proangiogenic factors such as platelet-derived growth factor and basic 
fibroblast growth factor through a novel mechanism. It has been made up in a 
topical preparation that can sustain therapeutic concentrations in the posterior 
segment of the eye. The formulation; OHR-102 (0.2% squalamine lactate 
ophthalmic solution) was evaluated in a study called ‘IMPACT’. In this phase II 
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study, 142 patients were given intravitreal ranibizumab monthly prn, and were 
randomized to receive twice daily drops of either OHR-102 or placebo. At 9 
months in the 94 of those with occult CNV of less than 10mm2 area, those on 
ranibizumab alone gained a mean of 5.7 letters, while those on squalamine 
drops too gained a mean of 11.0 letters, with no difference in the number of 
ranibizumab injections given between the two groups. A phase III study is 
ongoing (ClinicalTrials.gov Identifier: NCT02727881). Another innovation that 
may obviate the need for patients to undergo regular intravitreal injections is 
being investigated in the ‘LADDER’ trial: a port delivery system 
(ClinicalTrials.gov Identifier: NCT02510794). The port is a reservoir that is 
implanted into the eye, but allows external access so it can be flushed out and 
refilled. The LADDER trial is a phase II trial in which 3 concentrations of 
reservoir-based ranibizumab are being evaluated, in comparison to monthly 
intravitreal injections. As the delivery system elutes the drug over a prolonged 
period of time, it is hoped that the frequency of refill may be less than monthly. 
Results are expected in 2018. 
 
 
DRY AMD  
 
Subtitle: Inhibiting the visual cycle 
As well as these fascinating options on the horizon for nvAMD, several 
innovations may allow us to treat atrophic AMD. Visual cycle modulation aims 
to prevent RPE cell death. The principle is in effect visual cycle inhibition. Why 
would this be desirable? A by-product of the visual cycle is A2E, which has 
pathologic effects: generation of reactive oxygen intermediates, complement 
activation and up-regulation of VEGF. Slowing the cycle may impair 
photoreceptor recovery but also may reduce A2E accumulation. Fenretinide is 
a synthetic vitamin A derivative. Vitamin A, necessary to keep the visual cycle 
going, is transported from the liver to the eye by being carried on retinal 
binding protein. Fenretinide prevents this by attaching to retinol binding 
protein end ensuring excretion of the transport protein in the urine, thus 
ensuring less vitamin A is delivered to the eye. It has been used in trials for 
over 25 years on an estimated 9000 patients as a potential treatment for 
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several conditions, including rheumatoid arthritis, psoriasis and cancer (Mata, 
Lichter et al. 2013). In these trials it was found to be safe but in general 
success was limited, and a side effect was delayed dark adaptation. For 
atrophic AMD, a phase II trial randomized 246 patients to once daily oral 
placebo, 100g or 300g fenretinide (Mata, Lichter et al. 2013). Delayed dark 
adaptation and reduced night vision, as assessed by questionnaires, was 
detected in approximately 40% of those receiving fenretinide but in 30% of 
those on placebo. Reduced GA growth rates at 2 years were seen in those on 
fenretinide compared to placebo only in those in whom the serum retinal 
binding protein levels were reduced to under a low threshold, and even then 
only a trend was observed rather than a statistically significant difference. 
Interestingly any clinical effects on GA were seen only after a year of 
treatment, suggesting that the eyes may have mechanisms to maintain 
vitamin A levels in times of deficiency. In contrast to the lack of apparent 
benefit for atrophic AMD, of note in this trial was that the incidence of CNV 
was significantly less in the treatment arms than the placebo arms, at 
approximately 20% versus 9% over 2 years. Thus fenretinide’s place may lie 
on the menu of treatments for nvAMD. 
 
Subtitle: ‘The complement system’ 
 
The complement cascade is becoming well known to retinal specialists, given 
the multiplicity of genetic and pathological evidence that complement cascade 
overactivity is central to the pathogenesis of AMD (van Lookeren Campagne, 
Strauss et al. 2016). The complement cascade describes part of the innate 
immune system: a set of reactions in which proteins are serially activated in 
response to a perceived threat, such as an invading microorganism or foreign 
material. The resulting attack aims to neutralize the threat, but if the 
complement system is activated, for example by elements in drusen, collateral 
damage can occur. By slowing the complement cascade, complement 
inhibition (CI) aims to reduce collateral damage. Eculizumab is an inhibitor of 
C5, one of the complement proteins in the cascade. It is used for the 
treatment of two non-ophthalmic diseases, haemolytic uraemic syndrome and 
paroxysmal nocturnal haemoglobinuria. The ‘COMPLETE” study enrolled 30 
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patients with atrophic AMD to receive eculizumab intravenously at intervals, or 
placebo, for 6 months (Yehoshua, de Amorim Garcia Filho et al. 2014). 
However there was no difference in GA lesion growth between treatment and 
placebo arms, as measured using OCT. A list of possible explanations is 
interesting to consider (Yehoshua, de Amorim Garcia Filho et al. 2014). 
Systemic delivery, shown to be safe and assumed to cause adequate 
complement inhibition in the choroid, speculatively did not achieve this where 
it was perhaps needed, in the retina. Perhaps C5 was the wrong target, and 
inhibition of earlier steps of the cascade was needed. Perhaps a larger or 
longer study was needed, or one with a different means of measuring the 
outcome. It may be that complement has no role in GA growth, but another 
trial suggests CI is a useful approach. ‘MAHALO’ was a phase II trial 
investigating an anti-factor D drug, lampalizumab (Regillo C 2013). One 
hundred and twenty-nine participants with GA were randomized twice: to 
either intravitreal lampalizumab or sham injection, and to either monthly or 
bimonthly treatment. Change in atrophic AMD was measured at 18 months 
using autofluorescence. There was a 20.4% reduction in geographic atrophy 
(GA) progression in those receiving lampalizumab compared to those 
receiving sham. Intriguingly, in the 57% of participants who had a specific 
genetic change known to be associated with increased risk of AMD, in the 
gene CFI, the reduction in GA progression was 44% with lampalizumab 
compared to sham. While the numbers of patients in this genetic subgroup 
was not adequate for statistical significance to be reached, the finding brought 
to life the possibility of genetically testing patients to assess which treatment 
may be most effective for them. ‘CHROMA’ (ClinicalTrials.gov Identifier: 
NCT02247479) and ‘SPECTRI’ (ClinicalTrials.gov Identifier: NCT02247531) 
are two phase 3 trials investigating lampalizumab for atrophic AMD, aiming to 
recruit almost 1000 participants and expected to finish data collection in 
November 2018. 
 
Subtitle ‘Replacing RPE cells’ 
Can RPE cells, or their function, be replaced? Many approaches to replacing 
their function have been tried (eyewiki.aao.org/Retina_Prosthesis, accessed 
December 2016). One is the Argus II system (Ho, Humayun et al. 2015). 
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Glasses are worn which have a small central camera. The camera collects the 
image and sends it to a visual processing unit (VPU), worn by the patient. The 
VPU down samples the information, though the user has some control over 
image processing, for example being able to manipulate the contrast. A 
transmitter coil on the side of the glasses sends information wirelessly to a 
receiving antenna, fixed to the sclera under the lateral rectus and a scleral 
band. This is attached in turn to an electrode array tacked onto the epiretinal 
surface at the macula. The electrodes emit pulses of electricity, the amplitude 
of which corresponds to the brightness of the scene at that location. The 
patient receives visual ‘percepts’, and there is a learning curve to interpret 
them. The Argus II trial investigated the device not on patients with AMD, but 
on patients with no or bare light perception due to retinitis pigmentosa (RP), 
but the model, or the principles behind it, may have relevance for atrophic 
AMD in the future. In the trial the primary efficacy outcomes were 3 computer-
based visual tasks, developed with input from the low vision community: 
touching a white square presented at random on a black touchscreen, 
identifying the direction of movement of a white bar across the same screen 
and a grating VA assessment (Ho, Humayun et al. 2015). Thirty participants 
acted as their own controls by simply switching the device on or off. At 3 
years, visual function in all 3 tasks improved with the device on, and other 
than in 1 subject in whom the device was explanted due to recurrent 
conjunctival erosion, all devices were technically reliable. Serious adverse 
events included hypotony in 4, presumed endophthalmitis in 3 (all culture 
negative), retinal detachment in 2, infective keratitis in 1 and a corneal melt in 
1, but all were treatable. In the USA, despite the trial being small, the FDA 
approved the system for patients with end-stage RP, given that the degree of 
visual loss was profound, and that the rate of adverse events was said to be 
similar to that seen in glaucoma drainage devices. The 5-year results on 24 
patients indicated ongoing safety and visual benefits (da Cruz, Dorn et al. 
2016), and the Argus II is the only retinal prosthesis approved in the USA, 
Europa and Canada. Over 200 patients have had the Argus II system 
implanted to date. 
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Subtitle ‘stem cells’ 
Most cells in our body are specialized for specific roles: as liver cells, 
photoreceptors, skin cells or muscle cells for example. However all cells start 
with the potential, in theory, to differentiate into any cell in the body: they are 
pluripotent. Stem cells have this potential, and often make headlines as 
scientific breakthroughs are reported on their use to replace or recreate 
tissues. Stem cells can be found in the adult body in certain sites, such as the 
edge of the cornea, but can be difficult to harvest. Embryonic sources of stem 
cells raise ethical concerns to many. However John Gurdon and Shiya 
Yamanoka won the Nobel prize in medicine in 2012 
(https://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/popular-
medicineprize2012.pdf, accessed December 2016) for starting with mature 
skin cells, and ‘dedifferentiating’ them by adding four proteins, termed the 
‘Yamanaka Factors’, to form ‘induced pluripotent stem cells’ (iPSCs). These 
iPSCs have the potential, in theory, to form any cell type in the body and 
therefore offer new hope for many diseases, including diabetes mellitus, 
Parkinsons disease and Alzheimers, as well as AMD. Although there are 
challenges to overcome in the use of iPSCs, including post-transplant 
survival, and limiting tumorgenicity, the remarkable discovery of this means to 
create an unlimited source of stem cells not only overcomes ethical objections 
associated with the use of embryonic stem cells, but may provide a source of 
cells that, once differentiated, can be transplanted without concerns about 
immune rejection, as they could originate from the patient due to receive the 
transplant. The use of iPSCs in clinics is not close, but they have been used 
to reliably create human RPE cells, and several trials for atrophic AMD are 
ongoing (Fields, Cai et al. 2016). 
It is clear that there is currently a great effort in the vision science community 
to develop new approaches to treating both nvAMD and atrophic AMD. We 
live in interesting times in this regard, and as some of these and other yet 
unnoticed therapies become a reality for our patients, our professional 
practice will become ever more interesting. As patients become more 
informed about management options for their own conditions, it is incumbent 
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on us, as optometrists and ophthalmologists, to keep at least as up to date as 
our patients. We will need to be able to translate and temper information 
publically available online and in the popular press and to recommend the 
best treatment for the individual in front of us. 
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